Delayed cerebral ischaemia prevention and treatment after aneurysmal subarachnoid haemorrhage: a systematic review
- PMID: 27160932
- PMCID: PMC4913393
- DOI: 10.1093/bja/aew095
Delayed cerebral ischaemia prevention and treatment after aneurysmal subarachnoid haemorrhage: a systematic review
Abstract
: The leading cause of morbidity and mortality after surviving the rupture of an intracranial aneurysm is delayed cerebral ischaemia (DCI). We present an update of recent literature on the current status of prevention and treatment strategies for DCI after aneurysmal subarachnoid haemorrhage. A systematic literature search of three databases (PubMed, ISI Web of Science, and Embase) was performed. Human clinical trials assessing treatment strategies, published in the last 5 yr, were included based on full-text analysis. Study data were extracted using tables depicting study type, sample size, and outcome variables. We identified 49 studies meeting our inclusion criteria. Clazosentan, magnesium, and simvastatin have been tested in large high-quality trials but failed to show a beneficial effect. Cilostazol, eicosapentaenoic acid, erythropoietin, heparin, and methylprednisolone yield promising results in smaller, non-randomized or retrospective studies and warrant further investigation. Topical application of nicardipine via implants after clipping has been shown to reduce clinical and angiographic vasospasm. Methods to improve subarachnoid blood clearance have been established, but their effect on outcome remains unclear. Haemodynamic management of DCI is evolving towards euvolaemic hypertension. Endovascular rescue therapies, such as percutaneous transluminal balloon angioplasty and intra-arterial spasmolysis, are able to resolve angiographic vasospasm, but their effect on outcome needs to be proved. Many novel therapies for preventing and treating DCI after aneurysmal subarachnoid haemorrhage have been assessed, with variable results. Limitations of the study designs often preclude definite statements. Current evidence does not support prophylactic use of clazosentan, magnesium, or simvastatin. Many strategies remain to be tested in larger randomized controlled trials.
Clinical trial registration: This systematic review was registered in the international prospective register of systematic reviews.
Prospero: CRD42015019817.
Keywords: brain ischaemia; subarachnoid haemorrhage; vasospasm, intracranial.
© The Author 2016. Published by Oxford University Press on behalf of the British Journal of Anaesthesia. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Figures

Similar articles
-
Clinical Evidence for Intravenous Milrinone to Treat Secondary Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage-A Narrative Review.Acta Neurochir Suppl. 2025;136:3-9. doi: 10.1007/978-3-031-89844-0_1. Acta Neurochir Suppl. 2025. PMID: 40632248 Review.
-
Interventions for altering blood pressure in people with acute subarachnoid haemorrhage.Cochrane Database Syst Rev. 2021 Nov 17;11(11):CD013096. doi: 10.1002/14651858.CD013096.pub2. Cochrane Database Syst Rev. 2021. PMID: 34787310 Free PMC article.
-
Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage.Cochrane Database Syst Rev. 2022 Nov 9;11(11):CD001245. doi: 10.1002/14651858.CD001245.pub3. Cochrane Database Syst Rev. 2022. PMID: 36350005 Free PMC article.
-
Nicardipine Prolonged Release Implants for Prevention of Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis.J Stroke Cerebrovasc Dis. 2021 Oct;30(10):106020. doi: 10.1016/j.jstrokecerebrovasdis.2021.106020. Epub 2021 Aug 5. J Stroke Cerebrovasc Dis. 2021. PMID: 34365121
-
Intraoperative mild hypothermia for postoperative neurological deficits in people with intracranial aneurysm.Cochrane Database Syst Rev. 2016 Mar 22;3(3):CD008445. doi: 10.1002/14651858.CD008445.pub3. Cochrane Database Syst Rev. 2016. PMID: 27000210 Free PMC article.
Cited by
-
Chronological Change of the Clinical Features and Treatment Outcomes for Subarachnoid Hemorrhage in Japan: A Multicenter Retrospective Study.Neurol Med Chir (Tokyo). 2023 Oct 15;63(10):464-472. doi: 10.2176/jns-nmc.2023-0004. Epub 2023 Aug 23. Neurol Med Chir (Tokyo). 2023. PMID: 37612120 Free PMC article.
-
High Mobility Group Box-1 and Blood-Brain Barrier Disruption.Cells. 2020 Dec 10;9(12):2650. doi: 10.3390/cells9122650. Cells. 2020. PMID: 33321691 Free PMC article. Review.
-
The Local Intraarterial Administration of Nimodipine Might Positively Affect Clinical Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage and Delayed Cerebral Ischemia.J Clin Med. 2022 Apr 5;11(7):2036. doi: 10.3390/jcm11072036. J Clin Med. 2022. PMID: 35407643 Free PMC article.
-
Effect of nimodipine combined with atorvastatin calcium on microinflammation and oxidative stress levels in patients with cerebral vasospasm after subarachnoid hemorrhage.Pak J Med Sci. 2023 Mar-Apr;39(2):434-438. doi: 10.12669/pjms.39.2.6721. Pak J Med Sci. 2023. PMID: 36950409 Free PMC article.
-
Cerebral artery myogenic reactivity: The next frontier in developing effective interventions for subarachnoid hemorrhage.J Cereb Blood Flow Metab. 2018 Jan;38(1):17-37. doi: 10.1177/0271678X17742548. Epub 2017 Nov 14. J Cereb Blood Flow Metab. 2018. PMID: 29135346 Free PMC article. Review.
References
-
- van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet 2007; 369: 306–18 - PubMed
-
- Rinkel GJ, Algra A. Long-term outcomes of patients with aneurysmal subarachnoid haemorrhage. Lancet Neurol 2011; 10: 349–56 - PubMed
-
- Dodel R, Winter Y, Ringel F et al. . Cost of illness in subarachnoid hemorrhage: a German longitudinal study. Stroke 2010; 41: 2918–23 - PubMed
-
- Kassell NF, Torner JC, Jane JA, Haley EC Jr, Adams HP. The International Cooperative Study on the Timing of Aneurysm Surgery. Part 2: surgical results. J Neurosurg 1990; 73: 37–47 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical